Thomas Schinecker became CEO of Roche in March.
Keystone
Swiss pharmaceuticals group Roche is not ruling out further acquisitions.
This content was published on
2 minutes
Keystone-SDA/ds
But a major takeover must make “scientific and financial sense”, says the company’s CEO, Thomas Schinecker.
Interviewed on Sunday in the NZZ am Sonntag, he says he does not want to speculate on figures.
Schinecker has been at the helm of the Basel-based group since March. The worst approach, he says, would be “for the new guy to come in and say this is how we do it”. His task is to create the framework conditions so that changes can be implemented as quickly as possible, he adds.
Highly innovative projects
He says he has noticed a potential for improvement in the quality of research projects. When it comes to highly innovative molecules, the pharmaceutical group is at the forefront, he explains. But “it’s true that we also have a number of projects where we’re only in the middle of the pack”.
Future investments will therefore be geared more towards highly innovative projects, he continues, stressing that the most promising projects must also progress more rapidly.
Roche’s three research centers in Basel, California and Japan will remain independent, according to the CEO, who does not envisage any reorganisation. “Such a measure would lead to insecurity among employees and paralyze the organization for years to come,” he says.
More
More
The end of affordable medicine
This content was published on
Pharma companies are close to a cure for cancer, but will the hefty price tags make treatments unaffordable for most of the world?
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles. You can find them here.
If you want to know more about how we work, have a look here, and if you have feedback on this news story please write to english@swissinfo.ch.
Popular Stories
More
Multinational companies
Azeri fossil-fuel cash cow brings controversy to Switzerland
Is artificial intelligence an advantage or a disadvantage for workers?
What is your experience with AI at work? Have you already used it? Has it helped you work better? Or has it caused you more stress, more work or caused you to lose your job? Tell us about your experiences!
Swiss price watchdog slams excessive prices for generic medicines
This content was published on
The cheapest generic medicines available in Switzerland are more than twice as expensive as in other countries, according to a study by the Swiss price watchdog.
Nature should not figure in net zero calculations: academic study
This content was published on
The natural removal of CO2 from the atmosphere by forests or oceans should not be included in the net-zero balance of climate protection measures, argue researchers.
This content was published on
None of the 15 major Swiss retail banks is meeting international climate and biodiversity targets, according to a ranking by WWF Switzerland.
This content was published on
Nestlé's new CEO Laurent Freixe, has presented plans for the future of the world's largest food company, after his first few weeks in office.
Swiss foreign minister calls on Moscow to end Ukraine war
This content was published on
It's high time Moscow ended its war against Ukraine, Swiss foreign minister Ignazio Cassis tells the UN Security Council.
This content was published on
The only alternative to the UN Palestinian agency’s work in Gaza is to allow Israel to run services there, Philippe Lazzarini, UNRWA Commissioner-General, told reporters in Geneva on Monday.
Study reveals food culture differences between Switzerland and neighbours
This content was published on
Three-quarters of Swiss people consider eating to be a pleasurable, social activity, a new survey reveals. Healthy eating, however, plays a much less important role, it found.
Roche to focus on R&D, no job cuts in 2023, says new CEO
This content was published on
The Swiss pharma giant intends to invest more in research and development this year, according to Roche’s new CEO Thomas Schinecker.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.